https://nl.marketscreener.com/koers/aandeel/SYNDAX-PHARMACEUTICALS-IN-16725742/nieuws/Syndax-Pharmaceuticals-kondigt-Pivotal-AUGMENT-101-studie-van-Revumenib-in-recidiverende-recidiveren-44979463/?utm_source=telegram&utm_medium=social&utm_campaign=share